ImmunoGen (IMGN) Earns Daily Media Impact Rating of 0.16
News coverage about ImmunoGen (NASDAQ:IMGN) has trended somewhat positive on Wednesday, according to Accern. The research firm identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. ImmunoGen earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 45.8114403507807 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the news headlines that may have impacted Accern Sentiment’s scoring:
- FDA Finalizes Review Of ImmunoGen, Inc. (NASDAQ:IMGN) Investigational New Drug Application For IMGN632 (4-traders.com)
- ImmunoGen to Push Leukemia Candidate into Phase I Trial (finance.yahoo.com)
- BRIEF-Immunogen announces investigational new drug application for IMGN632 for hematological malignancies is active (reuters.com)
- Rare Stocks Roar Again After Tech Valuation: ImmunoGen, Inc. (NASDAQ:IMGN) – NASDAQ Times (nasdaqtimes.com)
- ImmunoGen Announces Investigational New Drug Application for IMGN632 for Hematological Malignancies is Active (finance.yahoo.com)
IMGN has been the subject of several research analyst reports. ValuEngine raised shares of ImmunoGen from a “sell” rating to a “hold” rating in a research note on Wednesday, June 21st. William Blair reaffirmed an “outperform” rating on shares of ImmunoGen in a research note on Monday, June 26th. Royal Bank Of Canada set a $5.00 price target on shares of ImmunoGen and gave the company a “hold” rating in a research note on Monday, June 26th. Jefferies Group LLC reaffirmed a “buy” rating and set a $6.00 price target on shares of ImmunoGen in a research note on Wednesday, June 28th. Finally, Zacks Investment Research downgraded shares of ImmunoGen from a “hold” rating to a “sell” rating in a research note on Monday, July 10th. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $8.05.
Shares of ImmunoGen (NASDAQ:IMGN) traded up 3.23% during trading on Wednesday, reaching $6.39. 2,579,834 shares of the company traded hands. The company’s market capitalization is $572.52 million. The firm’s 50 day moving average price is $7.13 and its 200-day moving average price is $5.68. ImmunoGen has a 52 week low of $1.51 and a 52 week high of $8.84.
ImmunoGen (NASDAQ:IMGN) last released its earnings results on Friday, July 28th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.17) by $0.07. The business had revenue of $39.02 million for the quarter, compared to analyst estimates of $30.59 million. ImmunoGen’s quarterly revenue was up 426.6% compared to the same quarter last year. During the same quarter last year, the company earned ($0.53) earnings per share. Equities analysts anticipate that ImmunoGen will post ($0.72) EPS for the current fiscal year.
In other ImmunoGen news, VP Craig Barrows sold 14,600 shares of the stock in a transaction that occurred on Wednesday, September 13th. The shares were sold at an average price of $6.95, for a total transaction of $101,470.00. Following the sale, the vice president now directly owns 51,100 shares in the company, valued at approximately $355,145. The transaction was disclosed in a document filed with the SEC, which is available through this link. 6.51% of the stock is owned by corporate insiders.
ImmunoGen Company Profile
ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.
Receive News & Ratings for ImmunoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.